Promacta Market Report 2026

The promacta market size has grown strongly in recent years. It will grow from $4.11 billion in 2025 to $4.46 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increasing diagnosis of immune thrombocytopenia, expansion of treatment options for aplastic anemia, improved clinical awareness of platelet disorders, availability of oral TPO receptor agonists, wider adoption of specialty hematology drugs.

The promacta market size is expected to see strong growth in the next few years. It will grow to $6.1 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to expansion of personalized hematology treatments, rising focus on rare blood disorder management, growing adoption of long-term outpatient therapies, increasing investments in hematology drug innovation, broader access to advanced thrombopoietin therapies. Major trends in the forecast period include increasing adoption of targeted thrombopoietin receptor therapies, rising focus on personalized treatment for thrombocytopenia, growing demand for oral platelet-stimulating drugs, expansion of indication-specific treatment protocols, enhanced emphasis on long-term patient management.

The rising prevalence of aplastic anemia is expected to drive the growth of the Promacta market in the coming years. Aplastic anemia is a rare condition in which the bone marrow is unable to produce an adequate number of blood cells, leading to fatigue, infections, and an elevated risk of bleeding. The occurrence of aplastic anemia is linked to factors such as exposure to toxic substances, certain medications, viral infections, autoimmune conditions, and genetic susceptibility. Promacta works by stimulating bone marrow stem cells to generate blood cells, thereby increasing platelet, red blood cell, and neutrophil counts. This reduces the need for blood transfusions and lowers the risk of bleeding and infections in patients with aplastic anemia. For instance, in April 2024, according to Anthony Nolan, a UK-based charity focused on leukemia and hematopoietic stem cell transplantation, approximately 100 to 150 individuals are diagnosed with aplastic anemia each year in the United Kingdom. Therefore, the growing prevalence of aplastic anemia is contributing to the expansion of the Promacta market.

The increase in healthcare expenditure is expected to further support the growth of the Promacta market going forward. Healthcare expenditure refers to the total spending on medical services, treatments, and healthcare infrastructure aimed at maintaining and improving individual and public health. Rising healthcare expenditure is driven by factors such as an aging population, technological advancements in medicine, and expanded health insurance coverage. Higher healthcare spending improves patient access to advanced treatments for thrombocytopenia and other blood disorders and enhances diagnostic capabilities, enabling earlier detection and greater adoption of Promacta. For instance, in May 2024, according to a report by the Office for National Statistics, a UK-based government department, total healthcare spending increased by 5.6% in nominal terms in 2023, reaching approximately £292 billion. These figures are based on more timely but less comprehensive data sources compared to previous years. Therefore, the rise in healthcare expenditure is driving the growth of the Promacta market.

The expanding geriatric population is also expected to propel the growth of the Promacta market in the coming years. The geriatric population consists of individuals aged 65 years and older, who often require specialized medical care to manage age-related health conditions. Growth in this population segment is driven by increased life expectancy, improvements in healthcare, declining birth rates, and advances in medical treatments. Promacta benefits the geriatric population by increasing platelet production in blood disorders, reducing bleeding risk, supporting immune function, and improving treatment outcomes, particularly among older adults who are more susceptible to platelet deficiencies. For instance, in January 2024, according to the Population Reference Bureau, a Kenya-based nonprofit organization, the number of people aged 65 and above in the United States is projected to rise from 58 million in 2022 to 82 million by 2050. Therefore, the increasing geriatric population is contributing to the growth of the Promacta market.

Major companies operating in the promacta market are Novartis AG, Amgen Inc, Pfizer Inc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Company, Roche Holding AG, Sanofi SA, AbbVie Inc, AstraZeneca plc, GlaxoSmithKline plc, Merck And Co Inc, Johnson And Johnson, CSL Behring, Grifols SA, Octapharma AG, Kedrion Biopharma, ADMA Biologics Inc, Bio Products Laboratory Ltd, Apotex Inc, Teva Pharmaceutical Industries Ltd, Sandoz International GmbH, Dr Reddys Laboratories Ltd.

North America was the largest region in the promacta market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the promacta market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the promacta market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the promacta market by increasing costs associated with imported active pharmaceutical ingredients, specialty excipients, packaging materials, and manufacturing inputs used in oral thrombopoietin receptor agonist production. Pharmaceutical supply chains in North America and Europe are most affected due to reliance on globally sourced raw materials, while Asia-Pacific faces cost pressure in contract manufacturing operations. These tariffs contribute to higher production costs and pricing pressures across hospital and retail pharmacy channels. However, they are also encouraging pharmaceutical companies to diversify sourcing strategies, invest in localized manufacturing, and strengthen regional supply resilience for critical hematology therapies.

The promacta market research report is one of a series of new reports that provides promacta market statistics, including promacta industry global market size, regional shares, competitors with a promacta market share, detailed promacta market segments, market trends and opportunities, and any further data you may need to thrive in the promacta industry. This promacta market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Promacta (eltrombopag) is an oral thrombopoietin receptor agonist (TPO-RA) that is used to stimulate platelet production in patients with specific blood disorders. It is mainly prescribed for conditions in which the body produces an insufficient number of platelets, increasing the risk of bleeding. Promacta helps lower the risk of bleeding in patients with reduced platelet counts.

The primary indications for Promacta include chronic immune thrombocytopenia, severe aplastic anemia, hepatitis C-associated thrombocytopenia, and others. Chronic immune thrombocytopenia (ITP) is a long-standing autoimmune condition characterized by low platelet levels, which can lead to excessive bleeding and requires treatment to suppress immune activity or enhance platelet production. Promacta is available in multiple dosage forms, including tablets and oral suspension, and is distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

The promacta market consists of sales of extended-release tablets and powder for suspension. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.